Avril McKean Dieser

Board Member
Ms. McKean Dieser, VP and Head of Legal Patient Evidence at UCB, Inc., brings 21+ years of pharmaceutical legal, regulatory, and corporate governance expertise, complemented by her legal, public administration, and English literature education.
See full team
Avril McKean Dieser
Background

Ms. McKean Dieser is currently the Vice President, Head of Legal Patient Evidence of UCB, Inc., a subsidiary of UCB, S.A., a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system, since August 2016, and previously from April 2008 to April 2013. At UCB, she leads a team of attorneys supporting UCB’s global assets, global payer functions, and regulatory, medical and patient communities, including clinical development. Ms. McKean Dieser was formerly a member of the AbbVie Inc. legal team providing global product support for the immunology and oncology franchises and was the government pricing lawyer for all pharmaceutical and combination products from May 2013 to July 2016. Prior to joining the pharmaceutical industry, Ms. McKean Dieser practiced corporate law in Atlanta, Georgia at two nationally recognized law firms. She earned her J.D. degree from The Catholic University Columbus School of Law and is admitted to practice law in the states of Georgia and Illinois. Prior to receiving her law degree, Ms. McKean Dieser received an M.A. in Public Administration from the University of Maryland, European Division and a B.A. degree in English Literature from Duquesne University. Ms. McKean Dieser lost her son, Edward, to Osteosarcoma in January 2024 at the age of 21. Ms. McKean Dieser is well qualified to serve as a director of the Company due to her substantial knowledge of the pharmaceutical regulatory and commercialization environment and more than 21 years of working experience in corporate controls and governance.

Our Pipeline

The Future of Cancer Treatment

OS Therapies is not just addressing Osteosarcoma. With the other uses of our HER2 target cancer immunotherapy and the addition of our OST-tADC tunable Antibody Drug Conjugate silicone linker platform, we are paving the way for the next-generation of cancer treatments.
Female chemist working on osteosarcoma treatments | OS TherapiesLab technician working on cancer treatments | OS TherapiesFemale chemist working on cancer treatments